open access
Vol 8, No 1 (2023)
Invited editorial
Published online: 2023-03-09
Get Citation
Bentracimab — a breakthrough for patients treated with antiplatelet agents?
1, 1
Affiliations- Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
open access
Vol 8, No 1 (2023)
INVITED EDITORIALS
Published online: 2023-03-09
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
Bentracimab — a breakthrough for patients treated with antiplatelet agents?
Journal
Issue
Article type
Invited editorial
Pages
5-7
Published online
2023-03-09
Page views
2162
Article views/downloads
352
DOI
Bibliographic record
Medical Research Journal 2023;8(1):5-7.
Authors
Piotr Adamski
Małgorzata Ostrowska
References (28)- Wallentin L, Becker R, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine. 2009; 361(11): 1045–1057.
- Bonaca M, Bhatt D, Cohen M, et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine. 2015; 372(19): 1791–1800.
- Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2018; 40(2): 87–165.
- Venetsanos D, Träff E, Erlinge D, et al. Prasugrel versus ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention. Heart. 2021; 107(14): 1145–1151.
- Mehran R, Baber U, Sharma S, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. New England Journal of Medicine. 2019; 381(21): 2032–2042.
- Adamski P, Skonieczny G, Hajdukiewicz T, et al. Reversal of Platelet Inhibition in Patients Receiving Ticagrelor. Reviews in Cardiovascular Medicine. 2022; 23(9): 300.
- Valgimigli M, Bueno H, Byrne R, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal. 2017; 39(3): 213–260.
- Teng R. Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clinical Pharmacokinetics. 2015; 54(11): 1125–1138.
- Godier A, Garrigue D, Lasne D, et al. Management of antiplatelet therapy for non elective invasive procedures of bleeding complications: proposals from the French working group on perioperative haemostasis (GIHP), in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR). Anaesthesia Critical Care & Pain Medicine. 2019; 38(3): 289–302.
- Godier A, Albaladejo P, Group to. Management of Bleeding Events Associated with Antiplatelet Therapy: Evidence, Uncertainties and Pitfalls. Journal of Clinical Medicine. 2020; 9(7): 2318.
- Zafar MU, Santos-Gallego C, Vorchheimer DA, et al. Platelet function normalization after a prasugrel loading‐dose: time‐dependent effect of platelet supplementation. Journal of Thrombosis and Haemostasis. 2013; 11(1): 100–106.
- Hansson EC, Hakimi CS, Åström-Olsson K, et al. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. British Journal of Anaesthesia. 2014; 112(3): 570–575.
- Scharbert G, Wetzel L, Schrottmaier W, et al. Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets. Transfusion. 2015; 55(6): 1320–1326.
- Bertling A, Fender AC, Schüngel L, et al. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor. Journal of Thrombosis and Haemostasis. 2018; 16(6): 1089–1098.
- O’Connor S, Amour J, Mercadier A, et al. Efficacy of Ex Vivo Autologous and In Vivo Platelet Transfusion in the Reversal of P2Y 12 Inhibition by Clopidogrel, Prasugrel, and Ticagrelor. Circulation: Cardiovascular Interventions. 2015; 8(11).
- Kruger P, Hirsh J, Bhagirath V, et al. In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets. Thrombosis and Haemostasis. 2018; 118(11): 1895–1901.
- Zafar M, Smith D, Baber U, et al. Impact of Timing on the Functional Recovery Achieved With Platelet Supplementation After Treatment With Ticagrelor. Circulation: Cardiovascular Interventions. 2017; 10(8).
- Teng R, Carlson GF, Nylander S, et al. Effects of autologous platelet transfusion on platelet inhibition in ticagrelor‐treated and clopidogrel‐treated subjects. Journal of Thrombosis and Haemostasis. 2016; 14(12): 2342–2352.
- Godier A, Taylor G, Gaussem P. Inefficacy of Platelet Transfusion to Reverse Ticagrelor. New England Journal of Medicine. 2015; 372(2): 196–197.
- Filaire L, Pham D, d’Ostrevy N, et al. Inefficacy of Platelet Transfusion in a Heart Transplant Patient Under Continuous Ticagrelor. Journal of Cardiothoracic and Vascular Anesthesia. 2017; 31(5): 1776–1778.
- Schoener L, Jellinghaus S, Richter B, et al. Reversal of the platelet inhibitory effect of the P2Y12 inhibitors clopidogrel, prasugrel, and ticagrelor in vitro: a new approach to an old issue. Clinical Research in Cardiology. 2017; 106(11): 868–874.
- Teng R, Oliver S, Hayes M, et al. Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects. Drug Metabolism and Disposition. 2010; 38(9): 1514–1521.
- Angheloiu G, Gugiu G, Ruse C, et al. Ticagrelor Removal From Human Blood. JACC: Basic to Translational Science. 2017; 2(2): 135–145.
- Buchanan A, Newton P, Pehrsson S, et al. Structural and functional characterization of a specific antidote for ticagrelor. Blood. 2015; 125(22): 3484–3490.
- Pehrsson S, Johansson KJ, Janefeldt A, et al. Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin. Journal of Thrombosis and Haemostasis. 2017; 15(6): 1213–1222.
- Bhatt D, Pollack C, Weitz J, et al. Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. New England Journal of Medicine. 2019; 380(19): 1825–1833.
- Summary of Phase 2B Study to Evaluate the Efficacy of PB2452 in Reversal of Ticagrelor in Subjects Aged 50-80. https://www.acc.org/latest-in-cardiology/clinical-trials/2022/04/01/03/34/bentracimab (13 February 2023).
- Characteristics of the REVERSE-IT study. https://clinicaltrials.gov/ct2/show/NCT04286438 (13 February 2023).